# A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

> **NCT07175038** · PHASE2 · RECRUITING · sponsor: **AllRock Bio, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Hypertension, Interstitial Lung Disease

## Interventions

- **DRUG:** ROC-101

## Key facts

- **NCT ID:** NCT07175038
- **Lead sponsor:** AllRock Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-03
- **Final completion:** 2029-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175038, "A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07175038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*